Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases
The Interleukin-5 (IL-5)-mediated pathogenic role of eosinophils in airway disorders including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and rare hyper-eosinophilic syndrome (HES) is well established. Me...
Saved in:
| Main Authors: | Dipti Gothi, Raghupathi Narasimhan, Randeep Guleria, Manu Chopra, Aanchal Gvalani, Rashmi Hegde |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-05-01
|
| Series: | Lung India |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/lungindia.lungindia_442_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-IL5/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated Systematic Review
by: Matteo Lazzeroni, et al.
Published: (2025-07-01) -
Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies
by: Mayu Shiomi, et al.
Published: (2025-04-01) -
Study protocol for a randomized double-blinded placebo-controlled trial on mepolizumab for patients with chronic rhinosinusitis with nasal polyps, NSAID exacerbated respiratory disease and asthma
by: Annina Lyly, et al.
Published: (2025-03-01) -
Two unique cases of eosinophilic granulomatosis with polyangiitis in childhood treated with anti-interleukin-5 therapy: infantile-onset and submandibular salivary gland involvement
by: Evangelia Constantine, et al.
Published: (2025-06-01) -
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study
by: Luisa Brussino, et al.
Published: (2025-03-01)